Ambros Therapeutics
Rare Disease Therapeutics · Biotechnology
Overview
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need.
Funding and backers
Team
201-500
employees, estimated range
Backers
1
RA Capital Management
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs AAVantgarde, AffiniaTX
backs AffiniaTX
Similar startupsby what they do, their industry and backers
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet…
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been…
Company Overview Rooted in two decades of discovery Santero Therapeutics is a Belgian biotechnology company developing first-in-class…
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines…
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc., today announced the appointments of John C. Jacobs and Scott Robertson t...
Read more
Report
Werewolf Therapeutics And Ambros Therapeutics Merge With $150 Million PIPE To Advance Phase III CRPS Drug Neridronate
Werewolf Therapeutics and Ambros Therapeutics have entered into a definitive all-stock merger agreement alongside an oversubscribed $150 million private placement that is expected to fund development of neridronate through pivotal Phase III results and a
Read more
Report
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-a
Read more
Report
Ambros Therapeutics, Ramaswamy's latest startup, launches with plans for pain treatment
Vivek Ramaswamy'a latest startup will develop and test a new treatment for Complex Regional Pain Syndrome.
Read more
Report